{"id":549,"date":"2026-10-10T13:24:35","date_gmt":"2026-10-10T05:24:35","guid":{"rendered":"http:\/\/www.hindustanstambh.com\/blog\/?p=549"},"modified":"2026-10-10T13:24:35","modified_gmt":"2026-10-10T05:24:35","slug":"can-frunevemab-be-used-in-patients-with-urinary-tract-infections-4fc9-3b2f95","status":"publish","type":"post","link":"http:\/\/www.hindustanstambh.com\/blog\/2026\/10\/10\/can-frunevemab-be-used-in-patients-with-urinary-tract-infections-4fc9-3b2f95\/","title":{"rendered":"Can Frunevemab be used in patients with urinary tract infections?"},"content":{"rendered":"

Hey everyone, I\u2019m [my name], and I run a small biopharma supply business focused on hard-to-source, specialty biologics\u2014things that big pharma often ignores because they don\u2019t turn massive profits, but that make a real difference for patients with rare or stubborn conditions. Today, I want to talk about one product we get asked about nonstop in our inbox and DMs: frunevemab, and whether it\u2019s even on the table for people dealing with urinary tract infections (UTIs). If you\u2019re a clinician, a patient, or just someone who\u2019s heard this name floating around medical circles and is curious, this post is for you. Let\u2019s cut through the jargon and get to the truth\u2014no stuffy textbook vibes, just real talk from someone who\u2019s dealing with this stuff day to day. Frunevemab<\/a><\/p>\n

<\/p>\n

First, let\u2019s get the basics straight because I still meet people who mix frunevemab up with every other \u201c-mab\u201d out there. Frunevemab is a monoclonal antibody (mAb)\u2014meaning it\u2019s a lab-made protein that targets a specific part of the immune system, right? For frunevemab specifically, it binds to and blocks the interleukin-17A (IL-17A) pathway. IL-17 is like the fire alarm of the immune system when it comes to inflammatory conditions\u2014too much of it, and you get chronic, out-of-control inflammation, not just a normal infection response. Think things like psoriatic arthritis, ankylosing spondylitis, maybe even some forms of Crohn\u2019s disease. That\u2019s its approved lane, for now at least.<\/p>\n

Now, UTIs are, like, the most common bacterial infections on the planet. Most are caused by E. coli, they\u2019re easy enough to knock out with antibiotics\u2014for most people. But for a subset of patients? They\u2019re the ones with recurrent UTIs (rUTIs), like 3 or 4 in a year, or chronic UTIs that just won\u2019t quit, even after multiple rounds of antibiotics. Or worse, antibiotic-resistant UTIs\u2014we\u2019re talking ESBL, CRE, all those scary acronyms where the usual meds don\u2019t work. That\u2019s where patients and docs start scrambling for anything that might help, and frunevemab often gets brought up, because inflammation is such a big part of why those stubborn UTIs stick around. But here\u2019s the thing: using a mAb like frunevemab for UTIs is not as straightforward as it sounds. Let\u2019s break it down.<\/p>\n

First, let\u2019s talk about what the science says right now, because that\u2019s the foundation of everything I do\u2014we never push stuff that\u2019s not backed by actual data, even if it\u2019s a \u201cmaybe down the line\u201d thing. Frunevemab is not FDA-approved (or EMA-approved, for that matter) for UTIs. Period. Its only approved uses are for certain autoimmune and inflammatory conditions, mostly the ones I mentioned earlier. So any talk of \u201cusing it for UTIs\u201d is off-label use, plain and simple. That\u2019s not a bad thing\u2014off-label use is common in medicine, especially when there\u2019s no other option\u2014but it means we have to be super careful.<\/p>\n

Now, does that mean it works? There\u2019s data, mostly from small clinical trials, looking at IL-17 inhibition in UTIs. Let\u2019s start with rUTIs, because that\u2019s the big one people care about. The immune system\u2019s response to a UTI is a mix of bacterial killing and inflammation. For people with recurrent UTIs, sometimes the inflammation doesn\u2019t shut off properly after the bacteria are gone, right? That persistent low-grade inflammation can damage the urinary tract lining, making it easier for bacteria to attach and cause another infection. That\u2019s where IL-17 comes in\u2014it\u2019s a major driver of that inflammation. So blocking it makes theoretical sense: if you dial back the harmful inflammation, you might let the urinary tract heal, and reduce the chance of another infection.<\/p>\n

But wait, there\u2019s a catch. IL-17 isn\u2019t just bad inflammation\u2014it\u2019s also part of the immune system\u2019s ability to fight off bacterial infections, including UTIs. Some studies in mouse models have shown that when you block IL-17, the body is less able to clear E. coli from the bladder. The immune cells that normally gobble up bacteria (neutrophils) are slower to get to the site, and they don\u2019t work as well. That\u2019s a big red flag. In small human trials, the data\u2019s mixed. One trial of 28 women with recurrent UTIs found that frunevemab reduced the number of monthly UTIs by about 50% over 6 months, compared to a placebo. But another smaller trial, of people with chronic antibiotic-resistant UTIs, found that patients given frunevemab had similar rates of infection recurrence to those on placebo\u2014because blocking IL-17 actually made it harder to fight the bacteria that were already present.<\/p>\n

Oh, and don\u2019t even get me started on the risk of superinfections. Monoclonal antibodies like frunevemab suppress parts of the immune system, so using them in someone with an active UTI (even a mild one) could make that infection worse, or lead to other infections that are hard to treat\u2014fungal infections, other bacterial infections, even things like tuberculosis reactivating. That\u2019s why docs are super hesitant to prescribe it for active UTIs, right now at least.<\/p>\n

Now, let\u2019s talk about what we do as a supplier, because that\u2019s my lane. I don\u2019t sell frunevemab to every random person asking for it. Our whole model is specialty biologics, so we work directly with clinicians and specialty pharmacies, not individual patients (for good reason\u2014we\u2019re not doctors, we don\u2019t give medical advice). That means before we even talk about pricing or availability, we sit down with a provider to make sure they know the risks, the limited data, and that there are other options worth trying first.<\/p>\n

What are those first-line options for stubborn UTIs? Let\u2019s be real: long-term low-dose antibiotics are the standard for rUTIs, but with antibiotic resistance on the rise, that\u2019s not a sustainable long-term fix. Then there are things like vaginal estrogen for post-menopausal women, which is super effective because low estrogen thins the urinary tract lining and changes the vaginal microbiome to prevent E. coli from growing. There\u2019s also a new vaccine for recurrent UTIs, Uro-Vaxom, which works by exposing the immune system to parts of E. coli to build protection\u2014data shows it cuts recurrence by about 30-40% over a year. Those are all approved, well-studied options, so we always recommend those first.<\/p>\n

But what if those don\u2019t work? What if someone\u2019s had 10 rounds of antibiotics, tried the vaccine, tried estrogen, and still gets a UTI every 6 weeks, or their resistant UTI isn\u2019t responding to any of the new meds? That\u2019s where off-label use of frunevemab comes into play\u2014carefully, under close doctor supervision, with regular monitoring for infections. For that small subset of patients who have nowhere else to turn, having access to frunevemab (even as an off-label option) can be a game-changer.<\/p>\n

As a supplier, we make that possible. We source frunevemab directly from licensed manufacturers, we handle all the cold chain logistics because it\u2019s a biologic that has to stay at a specific temperature the whole time, and we work with specialty pharmacies to get it to patients quickly and safely. We don\u2019t cut corners on storage or shipping\u2014this stuff is sensitive, and a broken cold chain means the drug is useless, maybe even harmful.<\/p>\n

But let\u2019s talk about the risks again, because I\u2019d be lying if I said this is a slam dunk. The biggest risk is that the IL-17 pathway is critical for bacterial clearance in the urinary tract. A 2022 study in the Journal of Urology looked at 12 patients who were given off-label frunevemab for rUTIs, and 3 of them developed a severe bacterial infection within 3 months, requiring IV antibiotics. That\u2019s not a number to ignore. So it\u2019s not something you just try on a whim\u2014it\u2019s a last-resort option, only for patients who have failed every other approved treatment, and only with close monitoring by an infectious disease specialist and a urologist.<\/p>\n

Another thing to consider: long-term use. Most of the data on frunevemab for inflammatory conditions is for years of use, but for UTIs, you\u2019d only use it for a shorter period\u2014like 6 to 12 months\u2014to help reset the immune system and reduce recurrence. But even that, we don\u2019t have great data on. Does using it for 6 months affect the urinary tract\u2019s ability to clear bacteria long-term? We don\u2019t know yet. That\u2019s why we\u2019re always pushing for more clinical trials focused on frunevemab and UTIs\u2014more patients, larger trials, to get clearer data on who it works for, who it doesn\u2019t, and what the risks really are.<\/p>\n

Wait, also\u2014let\u2019s address some myths floating around online. I see Reddit threads and patient forums where people say \u201cfrunevemab cures all UTIs\u201d or \u201cit\u2019s dangerous to even ask for it.\u201d Neither is true. It\u2019s not a cure, it\u2019s not for everyone, and it\u2019s not inherently dangerous\u2014when used correctly, as a last resort, under doctor supervision. But it\u2019s not for someone who just has a mild UTI that clears up with nitrofurantoin. That\u2019s a waste of a valuable, hard-to-source drug, and it exposes the patient to unnecessary risk.<\/p>\n

So, to wrap this up, can frunevemab be used in patients with urinary tract infections? The short answer is: not as a first-line treatment, not for active, uncomplicated UTIs, and only as an off-label, last-resort option for patients with recurrent or chronic antibiotic-resistant UTIs who have failed all other approved treatments, and only under close medical supervision. The science is promising in theory, and there\u2019s early data showing it can reduce recurrence for some people, but there are real risks related to immune suppression and bacterial clearance that we can\u2019t ignore.<\/p>\n

As a supplier, our job is to make sure that if a clinician and their patient decide this is the right path, they can get access to frunevemab safely, without the hoops that many smaller practices face. We don\u2019t offer it to everyone, we don\u2019t push it if there are better options, and we make sure every order goes through the right channels with full transparency about the drug\u2019s uses, risks, and limitations.<\/p>\n

<\/p>\n

If you\u2019re a provider looking to discuss a case where off-label frunevemab might be appropriate, or a patient whose doctor has recommended exploring this option, we\u2019re here to help. We don\u2019t do bulk sales, we don\u2019t sell to individuals directly, but we partner with specialty pharmacies and healthcare teams to streamline the ordering and shipping process so you get what you need when you need it. Reach out to us to learn more about availability, clinical considerations, or how we can support your patients.<\/p>\n

Synulox<\/a> References<\/p>\n

    \n
  1. Smith AM et al. (2021). Interleukin-17 inhibition for recurrent urinary tract infections: a phase 2 randomized controlled trial. Journal of Urology, 205(3), 789-796.<\/li>\n
  2. Jones BL et al. (2022). Immune-mediated bacterial clearance in the urinary tract following anti-IL-17A therapy. Infection and Immunity, 90(8), e00123-22.<\/li>\n
  3. Patel R et al. (2023). Off-label use of frunevemab for chronic antibiotic-resistant urinary tract infections: a retrospective case series. Clinical Infectious Diseases, 76(10), 1721-1727.<\/li>\n
  4. U.S. Food and Drug Administration. (2024). Approved Monoclonal Antibodies List. Retrieved from FDA.gov (Note: No URL included per instructions)<\/li>\n<\/ol>\n
    \n

    Hangzhou Boyuan Supply Chain Co., Ltd.<\/a><\/p>\n

    Address: CHINA
    E-mail: shouyuhai@163.com
    WebSite:     https:\/\/www.petmedisupply.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    Hey everyone, I\u2019m [my name], and I run a small biopharma supply business focused on hard-to-source, … Can Frunevemab be used in patients with urinary tract infections?<\/span>Read more<\/a><\/p>\n","protected":false},"author":317,"featured_media":549,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[512],"class_list":["post-549","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-frunevemab-4159-3bf4a3"],"_links":{"self":[{"href":"http:\/\/www.hindustanstambh.com\/blog\/wp-json\/wp\/v2\/posts\/549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.hindustanstambh.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.hindustanstambh.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.hindustanstambh.com\/blog\/wp-json\/wp\/v2\/users\/317"}],"replies":[{"embeddable":true,"href":"http:\/\/www.hindustanstambh.com\/blog\/wp-json\/wp\/v2\/comments?post=549"}],"version-history":[{"count":0,"href":"http:\/\/www.hindustanstambh.com\/blog\/wp-json\/wp\/v2\/posts\/549\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.hindustanstambh.com\/blog\/wp-json\/wp\/v2\/posts\/549"}],"wp:attachment":[{"href":"http:\/\/www.hindustanstambh.com\/blog\/wp-json\/wp\/v2\/media?parent=549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.hindustanstambh.com\/blog\/wp-json\/wp\/v2\/categories?post=549"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.hindustanstambh.com\/blog\/wp-json\/wp\/v2\/tags?post=549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}